 |
Michael D. Howell, Ph.D. Science Advisory Board Member Dr. Michael Howell is a Co-Founder of Galileo Biosystems and scientific advisor to several startup biotech companies. Prior to Galileo, Dr. Howell was a faculty member at National Jewish Health and held roles of increasing responsibility at Boehringer Ingelheim, Immune Tolerance Network, MedImmune/AstraZeneca, Incyte Corporation and, most recently, DermTech. Throughout his career, he has led research and development teams dedicated to the discovery of novel therapies and the integration of precision and personalized medicine approaches to clinical development. His efforts have led to the approval of multiple therapies including Opzelura (ruxolitinib), Jakafi (ruxolitinib), Adbry/Adtralza (tralokinumab), Tezpire (tezepelumab), Skyrizi (rizankizumab), and Spevigo (spesolimab), and to other novel diagnostic approaches to patient treatment that have been highlighted in more than 60 publications and numerous patents. Dr. Howell received his Ph.D. in immunology from West Virginia University School of Medicine and completed his post-doctoral training at National Jewish Health. |